| # | Drug | Count |
|---|---|---|
| 0 | FINASTERIDE | 31 |
| 1 | INFLIXIMAB | 27 |
| 2 | ADALIMUMAB | 18 |
| 3 | INFLIXIMAB-DYYB | 18 |
| 4 | RISANKIZUMAB-RZAA | 16 |
| 5 | ACETAMINOPHEN | 7 |
| 6 | METHOTREXATE | 7 |
| 7 | METHOTREXATE SODIUM | 7 |
| 8 | SODIUM OXYBATE | 7 |
| 9 | UPADACITINIB | 7 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | INFLIXIMAB-DYYB | 18 | 0.0052 |
| 1 | ANTIHEMOPHILIC FACTOR (RECOMBINANT) PEGYLATED-AUCL | 3 | 0.0032 |
| 2 | COAGULATION FACTOR IX (RECOMBINANT), FC FUSION PROTEIN | 3 | 0.0012 |
| 3 | SUMATRIPTAN SUCCINATE AND NAPROXEN SODIUM | 1 | 0.0007 |
| 4 | FLUNISOLIDE | 1 | 0.0007 |
| 5 | ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC FUSION PROTEIN | 2 | 0.0005 |
| 6 | FINASTERIDE | 31 | 0.0005 |
| 7 | BRODALUMAB | 1 | 0.0005 |
| 8 | LANADELUMAB-FLYO | 1 | 0.0003 |
| 9 | C1 ESTERASE INHIBITOR RECOMBINANT | 2 | 0.0003 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-17 Receptor A Antagonist [EPC] | 1 | 0.0005 |
| 1 | Guanylate Cyclase-C Agonist [EPC] | 1 | 0.0005 |
| 2 | Plasma Kallikrein Inhibitor [EPC] | 1 | 0.0004 |
| 3 | 5-alpha Reductase Inhibitor [EPC] | 31 | 0.0003 |
| 4 | Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC] | 2 | 0.0002 |
| 5 | Interleukin-23 Antagonist [EPC] | 21 | 0.0002 |
| 6 | Bile Acid Sequestrant [EPC] | 2 | 0.0002 |
| 7 | Parenteral Iron Replacement [EPC] | 2 | 0.0001 |
| 8 | Provitamin D2 Compound [EPC] | 4 | 0.0001 |
| 9 | Antifibrinolytic Agent [EPC] | 1 | 0.0001 |